Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FT
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
Novo Nordisk is selling Wegovy faster than it can be made. It's scaling up production as well as acquiring more capacity.
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Novo Nordisk just acquired Catalent, a subcontractor for the company's drug production. Per the deal, Novo Nordisk will take over three of Catalent's production plants.
How Important Are Ozempic and Wegovy to Novo Nordisk's Business?
Novo Nordisk's obesity sales more than doubled last quarter. Ozempic and Wegovy account for a significant part of total revenue.
Bio-pharma services are key to our strategy: Novo Holdings CEO
Kasim Kutay, CEO of Novo Holdings, discusses Novo Holdings acquisition of U.S.-based medicines manufacturer Catalent.
Novo Holdings invests in hospital chain Manipal in India
Novo Holdings, the holding company of Novo Nordisk , said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, its largest investment in Asia to date.
Why Novo Nordisk Stock Crushed the Market on Monday
Its controlling shareholder has agreed to acquire U.S. contract manufacturer Catalent. The all-cash transaction's enterprise value is $16.5 billion.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming.
Big drug companies have substantial free cash flow from older, cash-cow drugs, manageable debt burdens, and investor pressure to find new growth opportunities.
Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4?
Novo Nordisk is one of the pharmaceutical stocks of the moment. And it just delivered an estimate-busting earnings report.
Novo Nordisk still a buy for Citi as return on capital hits 88%
Novo Nordisk (NYSE:NVO) remains a buy for US bank Citigroup even though it is only the second European company in history to pass the half-a-trillion mark after LVMH temporarily hit the landmark la...
Obesity product competition benefits companies and society: Novo Nordisk
Novo Nordisk CEO Lars Fruergaard Jørgensen speaks to CNBC following blockbuster earnings from Europe's largest company, driven by soaring demand for its obesity and diabetes drugs Wegovy and Ozempic.
Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared Holz
Jared Holz, Mizuho Securities, joins 'Fast Money' to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.
Novo Nordisk CFO discusses 36% surge in sales driven by Wegovy and Ozempic
Pharmaceutical giant Novo Nordisk (NVO) reported a 36% surge in sales thanks to high demand for weight loss drugs Wegovy and Ozempic. Novo Nordisk CFO Karsten Munk Knudsen joins Yahoo Finance Senio...
Novo Nordisk increasing supply of Wegovy as demand continues to grow
Novo Nordisk says it Is gradually ramping up supply of its sought-after drug Wegovy. However, the company is still warning patients demand will still outpace supply overall.
Related Companies